Apart from providing active ADAMTS13 to patients, a treatment has been developed that prevents the formation of VWF-rich microthrombi, which play a detrimental role in TTP pathophysiology. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.